SCHEMBL2733747

SCHEMBL2733747

CC(C)(C(=O)O)C(=O)NC[C@H](N)Cc1c[nH]c2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.55
KDM4E B2RXH2 2/20 0.55
MEN1 O00255 1/20 0.55
LMNA P02545 1/20 0.55
MPO P05164 1/20 0.55
TSHR P16473 1/20 0.55
BLM P54132 1/20 0.55
PMP22 Q01453 1/20 0.55
KMT2A Q03164 1/20 0.55
HIF1A Q16665 1/20 0.55
HTR2A P28223 2/20 0.54
ACE P12821 2/20 0.54
POLB P06746 2/20 0.52
APAF1 O14727 1/20 0.52
RECQL P46063 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
ADRB1 P08588 1/20 0.50
HTR1A P08908 1/20 0.50
ADRA2A P08913 1/20 0.50
SLC6A2 P23975 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2733750 1.00 MAPT (0.55) MAPTKDM4EMEN1LMNAMPO
SCHEMBL2733752 1.00 MAPT (0.55) MAPTKDM4EMEN1LMNAMPO
SCHEMBL10059278 0.91 HTR2A (0.54) MAPTKDM4EMEN1LMNAMPO
SCHEMBL15346967 0.91 HTR2A (0.54) MAPTKDM4EMEN1LMNAMPO
SCHEMBL6421208 0.89 HTR2A (0.52) MAPTKDM4EMEN1LMNAMPO
SCHEMBL15346977 0.89 HTR2A (0.52) MAPTKDM4EMEN1LMNAMPO
SCHEMBL15356237 0.87 MAPT (0.56) MAPTKDM4EMEN1LMNAMPO
SCHEMBL18780144 0.86 ACE (0.54) MAPTKDM4EMEN1LMNAMPO
SCHEMBL2732566 0.84 ACE (0.53) MAPTKDM4EMEN1LMNAMPO
SCHEMBL2732564 0.84 ACE (0.53) MAPTKDM4EMEN1LMNAMPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3756665-A1 INTERVAL THERAPY FOR THE TREATMENT OF EYE DISEASES Ramot at Tel-Aviv University Ltd. (IL) 2020-12-30 EP claimed
US-9629824-B2 Indole derivatives and process for their preparation RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2017-04-25 US claimed
US-20160220535-A1 INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2016-08-04 US claimed
US-9309196-B2 Indole derivatives and process for their preparation RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2016-04-12 US claimed
EP-2632897-B1 INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION MERZ PHARMA GMBH & CO KGAA (DE) 2014-10-01 EP claimed
US-20130289090-A1 INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION MERZ PHARMA GMBH & CO. KGAA (DE) 2013-10-31 US claimed
EP-2632897-A1 INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION Merz Pharma GmbH & Co. KGaA (DE) 2013-09-04 EP claimed
WO-2012055945-A1 INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION MERZ PHARMA GMBH & CO. KGAA (DE) 2012-05-03 WO claimed
US-20220193035-A1 INDOLE COMPOUNDS FOR USE IN NEURORESTORATION GALIMEDIX THERAPEUTICS, INC. (US) 2022-06-23 US disclosed
EP-3756665-A1 INTERVAL THERAPY FOR THE TREATMENT OF EYE DISEASES Ramot at Tel-Aviv University Ltd. (IL) 2020-12-30 EP disclosed
US-9717772-B2 Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2017-08-01 US disclosed
US-9629824-B2 Indole derivatives and process for their preparation RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2017-04-25 US disclosed
US-20160220535-A1 INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2016-08-04 US disclosed
US-9309196-B2 Indole derivatives and process for their preparation RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2016-04-12 US disclosed
EP-2632897-B1 INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION MERZ PHARMA GMBH & CO KGAA (DE) 2014-10-01 EP disclosed
US-20130289090-A1 INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION MERZ PHARMA GMBH & CO. KGAA (DE) 2013-10-31 US disclosed
US-20130289090-A1 INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION MERZ PHARMA GMBH & CO. KGAA (DE) 2013-10-31 US disclosed
EP-2632897-A1 INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION Merz Pharma GmbH & Co. KGaA (DE) 2013-09-04 EP disclosed
WO-2012055945-A1 INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION MERZ PHARMA GMBH & CO. KGAA (DE) 2012-05-03 WO disclosed
WO-2012055945-A1 INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION MERZ PHARMA GMBH & CO. KGAA (DE) 2012-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220193035-A1 INDOLE COMPOUNDS FOR USE IN NEURORESTORATION AANAT, INMT, TPH2 MAPT 23/4885KDM4E 2447/4885MEN1 1906/4885
US-20130289090-A1 INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION HCRTR1, APP, C1R MAPT 342/4885KDM4E 4491/4885MEN1 979/4885
US-20160220535-A1 INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION HCRTR1, APP, C1R MAPT 227/4885KDM4E 4519/4885MEN1 853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.